Association Between ABO Polymorphism and Gastric/Colorectal Cancers

November 27, 2023 updated by: Wesam Ashraf Soliman Ahmed, Assiut University
To assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/or colorectal cancers relative to healthy controls by real time PCR.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The ABO blood group system was discovered by the Austrian pathologist Karl Landsteiner in 1901, who classified the blood groups based on the presence of A and B antigens on the surface of red blood cells after noting patterns of agglutination during blood transfusion. Since the discovery of the ABO blood group system , several studies investigating the relationship between the ABO blood group system and various diseases have been conducted , cancer included .

First association between ABO blood group and cancer risk was reported in 1953 in The English patients with gastric cancer.

Gastric cancer is one of the most common malignant tumors of the digestive system , worldwide, gastric cancer is still the fourth most common cancer and the second most common cause of cancer death . The development of gastric cancer is caused by the interaction of genetic and environmental factors , ABO blood grouping is one of the most stable genetic factors.

This association is also observed with other gastrointestinal malignancies, including colorectal cancer which considered the third common cancer in both women and men and responsible for approximately 10% of all cancers, and the third most common cause of cancer related mortality for men and fourth for women .

The ABO is also the first blood group system defined at the gene level . SNP is a single nucleotide polymorphism, is a germ line substitution of a single nucleotide at a specific position in the genome that is present in a sufficiently large fraction of considered population , SNP may act as biological markers, as they can relate to the genes that are associated with various complex diseases as heart diseases, diabetes, cancer … etc.

In previous studies , significant association between ABO gene SNP (rs8176746) , H. Pylori infection, gastric and pancreatic cancer were found , as they observed that this gene SNP was associated with decreased risk of these disorders.

Study Type

Observational

Enrollment (Estimated)

184

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Patients that histopathologically confirmed gastric and/or colorectal cancer, males and females.

Description

Inclusion Criteria:

  • Patients that histopathologically confirmed gastric and/or colorectal cancer.
  • males and females.

Exclusion Criteria:

  • Presence of other haematological , autoimmune disorders or other malignancies.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
cases
Patients that histopathologically confirmed gastric and/or colorectal cancer, males and females.
Genetic: quantitative Real-time PCR
: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/colorectal cancers relative to healthy controls.
Time Frame: Baseline

assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/colorectal cancers relative to healthy controls by real-time PCR.

and determine the impact of ABO phenotype and genotype on risk of development of gastric and/or colorectal cancers.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2023

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

January 1, 2026

Study Registration Dates

First Submitted

November 19, 2023

First Submitted That Met QC Criteria

November 27, 2023

First Posted (Actual)

November 29, 2023

Study Record Updates

Last Update Posted (Actual)

November 29, 2023

Last Update Submitted That Met QC Criteria

November 27, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ABO in gastric/colorectal canc

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Clinical Trials on quantitative Real-time PCR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe